We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Wearable Cardioverter Defibrillator Protects Patients at High Risk of Sudden Cardiac Arrest

By HospiMedica International staff writers
Posted on 30 Jan 2024

Sudden cardiac arrest (SCA) is a leading cause of death in the United States and in Europe where out-of-hospital SCA remains a significant problem with approximately only about 10% of patients surviving. More...

Traditional garment-based Wearable Cardioverter Defibrillators (WCDs) have demonstrated the ability to treat SCA, although challenges related to patient comfort and compliance have resulted in avoidable deaths and limited their widespread adoption. Now, a novel wearable patch defibrillator is designed to address the limitations with garment-based WCDs, paving the way for enhanced protection of patients with elevated risk of SCA.

The Jewel P-WCD (Patch-WCD) from Element Science (San Francisco, CA, USA) is a revolutionary wearable patch defibrillator that offers a new level of protection and peace of mind for those at risk of SCA. It can detect and treat specific life-threatening rhythms as soon as they happen, and offers dependable protection with nearly continuous wear-time compliance. Its discreet under-clothing design and sleek wearable technology allows it to be taken anywhere while allowing clinicians to engage with their patient’s care using the company’s streamlined, easy-to-use digital platform. The device is also compatible with daily activities like showering and moderate exercise.

The Jewel P-WCD, developed with a design focused on enabling better compliance that has been clinically shown to lead to the delivery of lifesaving therapy when required, may significantly increase the chances of survival in OHCA. The effectiveness of the Jewel defibrillator was confirmed in the Jewel EP Lab Study, in which 16 patients experiencing ventricular arrhythmias were successfully converted to a normal heart rhythm after a single therapeutic shock. The Jewel IDE Study, a pivotal study of 305 patients, demonstrated significant patient compliance and protected time resulting in a high number of successful patient saves and no deaths or serious adverse events related to the device. Element Science has now received the European Union’s CE mark certification and Great Britain’s UK Conformity Assessed (UKCA) marking for its novel P-WCD from its Notified Body, the BSI Group.

"Out-of-hospital SCA remains a significant problem in the United States and Europe with approximately only about 10% of patients surviving,” said Dr. Uday N. Kumar, Founder, President & CEO of Element Science. “The Jewel was developed to address the compliance issues of garment-based WCDs by focusing on user experience design and by incorporating advanced machine learning algorithms, both of which are approaches common in consumer wearables but relatively uncommon in medical device development. Gaining the CE mark under the rigorous European Union Medical Device Regulation (EU MDR) as well as the UKCA mark are testaments to the strength of the development, testing, and clinical results of the Jewel P-WCD.”

Related Links:
Element Science


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.